Fr532 THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDYBruce E. Sands, William J. Sandborn, Mary Ellen Frustaci et al.|Gastroenterology|2021Cited by 5
S748 Early PRO-2 Symptom Remission Following Guselkumab Induction Treatment: Results Through Week 12 of the Phase 2 GALAXI 1 StudyAnita Afzali, Walter Reinisch, William J. Sandborn et al.|The American Journal of Gastroenterology|2021Cited by 2
S857 Patient-Reported Outcomes of Response and Remission Following Guselkumab Induction Treatment as Measured by the Inflammatory Bowel Disease Questionnaire: Results Through Week 12 of the Phase 2 GALAXI 1 StudyDavid T. Rubin, Julián Panés, Bruce E. Sands et al.|The American Journal of Gastroenterology|2021Cited by 2